Next Generation Therapeutics Manufacturing
from humans, for humans
Immunoglobulin (Ig) products are sourced from blood and plasma donations.
Currently, an average of 10 plasma donations are required to produce a single dose of IvIg. We estimate Lyric's process can produce 1,000 or more doses from a single donor.
Lyric is building bioreactors that replicate biological tissue to produce human Ig.
Lyric's bioreactors are unique because they leverage a proprietary laser printed cellular substrate that supports ultra high-density cell growth. Our unique tissue engineering technology enables the expansion of cells from a single donor for continuous production of human immunoglobulin with a bioreactor you can hold in the palm of your hand.
Capturing the Power of Human Biology
Lyric Biosciences, Inc. is expanding biomanufacturing to human donor-derived biologics.
Using proprietary tissue engineering technology Lyric is developing high-density tissue mimicking bioreactors that will reduce Ig therapy dependence on human donation by several orders of magnitude.
................................................................................................................................................................
The Biotechnology Revolution was enabled by advances in biomanufacturing.
At Lyric our vision is eliminate global shortages of critical therapeutics by enabling scalable manufacturing of complex therapeutics. Today, access to life-saving medicines like insulin and monoclonal antibodies are taken for granted; however, just 50 years ago their use was severely limited because no means of scalable manufacturing existed.
................................................................................................................................................................
Millions of people still rely on medical treatment dependent on human donations.
Standard biomanufacturing processes cannot produce complex therapeutics. This results in high cost and limited access to life-saving therapies. Lyric is solving this problem. We are starting with a life-saving therapeutic used to treat over 100 different diseases, human immunoglobulin (IvIg, ScIg).
Making Medicine Limitless
Expanding Access To Life-Saving Therapies
Efficient Production
Reduce production costs of Ig by eliminating need to ship and process millions of gallons of plasma.
Stable and Scalable Supply
Alleviate donor dependency to facilitate better drug access and increase supply chain stability.
Higher Quality
Introduce manufacturing processes to improve product consistency and quality control.
Kayj Shannon
Co-Founder & CEO
Melanie Matheu, PhD
Co-Founder & CSO
Founding Team